Genitourinary Cancer

Featured

Conference Coverage
Advanced Oral Therapy Adherence Among Patients With Prostate Cancer
Patients with prostate cancer who were non-adherent to advanced oral therapies experienced substantially higher HCRU than those who were adherent.
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition…
Videos
Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC
Michaela Dinan, PhD, discusses results from a study which investigated real-world adherence and outcomes associated…
Videos
Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with…
Videos
Hospital Efficiency Impact on Quality of Prostate Cancer Care
Ravi Jayadevappa, PhD, MS, discusses the association between hospital efficiency and quality of care in African…

News

Health Care Spending for High-Resource Patients With Prostate Cancer
RT Added to ADT Cost-Effective vs ADT Alone for Metastatic Prostate Cancer
Comparative Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
Long-Term QOL in Prostate Cancer Treated With Ultra-Hypofractionation RT vs Conventionally Fractioned RT

Guideline Updates

AUA, ASTRO, and SUO Release Consensus Guideline on Advanced Prostate Cancer

Interviews

Novel Liquid Biopsy for Prostate Cancer Projected to Save Millions for US Health Care System

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

Podcast

Episode 52: Advances in Prostate Cancer With Neeraj Agarwal

Conference Coverage

Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
Back to Top